Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer. uri icon

Overview

abstract

  • In this issue of Cancer Cell, Lee and colleagues (2016) define the biologic role of MYCN in promoting prostate tumorigenesis and development of a neuroendocrine phenotype. This has important implications for the clinical management of neuroendocrine prostate cancer as Aurora A kinase inhibitors promoting N-Myc destabilization progress in the clinic.

publication date

  • April 11, 2016

Research

keywords

  • Carcinoma, Neuroendocrine
  • Prostatic Neoplasms

Identity

PubMed Central ID

  • PMC5550814

Scopus Document Identifier

  • 84962666154

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2016.03.023

PubMed ID

  • 27070695

Additional Document Info

volume

  • 29

issue

  • 4